

## **Erratum to: pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients**

**Gabriele Buda · Enrico Orciuolo · Sara Galimberti · Matteo Pelosini · Mario Petrini**

Published online: 4 March 2011  
© Springer-Verlag 2011

**Erratum to: Ann Hematol**  
**DOI 10.1007/s00277-010-1136-5**

The original version of this article unfortunately contained a mistake. The correct definition of Myocet® is given below.

Myocet® is a Non-pegylated liposomal doxorubicin (NPLD).

---

The online version of the original article can be found at doi: <http://dx.doi.org/10.1007/s00277-010-1136-5>.

---

G. Buda (✉) · E. Orciuolo · S. Galimberti · M. Pelosini · M. Petrini  
Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University,  
Via Roma 67,  
56100 Pisa, Italy  
e-mail: [ga.buda@libero.it](mailto:ga.buda@libero.it)